Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer: An Initial Report From the Surveillance, Epidemiology, and End Results Program
Caitlin C Murphy, David E Gerber, Sandi L Pruitt, Caitlin C Murphy, David E Gerber, Sandi L Pruitt
Abstract
Importance: The US cancer survivor population is rapidly growing. Cancer survivors are frequently excluded from cancer clinical trials and observational research.
Objective: To examine prevalence of prior cancer among individuals newly diagnosed with cancer.
Design, setting, and participants: Linked observations across the population-based Surveillance, Epidemiology, and End Results (SEER) program of cancer registries (1975-2013) for 740 990 persons newly diagnosed with cancer from January 2009 through December 2013. Prevalence of prior cancer was estimated by age (<65 years vs ≥65 years) and incident cancer type.
Main outcomes and measures: Prevalence of prior cancer was derived from SEER sequence numbers, which represent the order of all primary reportable tumors diagnosed in a lifetime. Incident cancers were categorized as: (1) first or only primary; (2) second order or higher primary in the same cancer site; and (3) second order or higher primary in a different cancer site.
Results: Of 765 843 incident cancers diagnosed between 2009 and 2013, 141 021 (18.4%) represented a second order or higher primary cancer. Overall, approximately one-fourth (25.2%) of older (≥65 years) and 11% of younger adults newly diagnosed with cancer had a history of prior cancer. Prevalence of prior cancer ranged from 3.5% to 36.9% according to incident cancer type and age, with most prior cancers diagnosed in a different cancer site.
Conclusions and relevance: A substantial proportion of patients diagnosed with incident cancer in the United States have survived a prior cancer. These patients may be excluded from clinical trials and underrepresented in observational research, and little is known about their treatment and survivorship needs. Understanding the nature and impact of prior cancer is critical to improving clinical trial accrual and generalizability, disease outcomes, and patient experience.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
References
- Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “Silver Tsunami”: Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States. Cancer Epidemiol Biomarkers Prev. 2016;25(7):1029–1036.
- de Moor JS, Mariotto AB, Parry C, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22(4):561–570.
- Hewitt M, Greenfield S, Stovall E. From Cancer Patient to Cancer Survivor: Lost in Transition. 2006.
- Leach CR, Weaver KE, Aziz NM, et al. The complex health profile of long-term cancer survivors: prevalence and predictors of comorbid conditions. J Cancer Surviv. 2015;9(2):239–251.
- Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12(1):20–37.
- Gerber DE, Laccetti AL, Xuan L, Halm EA, Pruitt SL. Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst. 2014;106(11).
- Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. J Natl Cancer Inst. 2015;107(4).
- Johnson C, Peace S, Adamo P, Fritz A, Percy-Laurry A, Edwards B. The 2007 multiple primary and histology coding rules. National Cancer Institute, Surveillance, Epidemiology and End Results Program. 2007.
- Gerber DE, Pruitt SL, Halm EA. Should criteria for inclusion in cancer clinical trials be expanded? J Comp Eff Res. 2015;4(4):289–291.
- Pruitt SL, Laccetti AL, Xuan L, Halm EA, Gerber DE. Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer. Br J Cancer. 2017;116(6):717–725.
- Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE. Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis. Lung Cancer. 2016;98:106–113.
- Bradley CJ, Yabroff KR, Mariotto AB, Zeruto C, Tran Q, Warren JL. Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011). J Clin Oncol. 2017:Jco2016694166.
- Murphy CC, Harlan LC, Lund JL, Lynch CF, Geiger AM. Patterns of Colorectal Cancer Care in the United States: 1990–2010. J Natl Cancer Inst. 2015;107(10).
- Charlton ME, Lin C, Jiang D, et al. Factors associated with use of preoperative chemoradiation therapy for rectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium. Am J Clin Oncol. 2013;36(6):572–579.
- Jackson GL, Melton LD, Abbott DH, et al. Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs. J Clin Oncol. 2010;28(19):3176–3181.
Source: PubMed